• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

oncolytic virus

Image of a neon sign with the word no lit up next to an unlit yes
Biotech

Replimune's request for melanoma approval rejected by FDA

Investors sent the biotech’s share price down 76% to below $3 in premarket trading.
Nick Paul Taylor Jul 22, 2025 8:45am
U turn turn around refocus pivot street sign

Theriva prioritizes oncolytic adenovirus at expense of GvHD drug

Mar 7, 2025 4:47am
pass the torch deal sell buy acquisition

4 years on from launch, IconOVir sells oncolytic virus to UroGen

Feb 20, 2025 9:12am
Wall Street stock exchange finance shares share price Nasdaq

Candel burns bright as phase 3 cancer win sends stock up 200%

Dec 11, 2024 9:49am
Graphic showing arrows missing the bullseye on a target

Transgene's viral cancer vaccine flunks midphase test

Oct 14, 2024 4:59am
one white and yellow capsule farther ahead than four other same-colored blue capsules

CG sets new bar in bladder cancer, months after huge IPO

May 3, 2024 11:23am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings